+39 06 5782665
contact@donawa.com
Italy - UK - USA

CLINICAL STUDY SUBMISSIONS

Donawa Lifescience Consulting (DLC) > Clinical Study Submissions > US IDE Applications and IRB Submissions

US IDE Applications and IRB Submissions

DLC Clinical Regulatory Unit services include:

  • Determination of Investigational Device Exemption (IDE) requirements for:

> IDE non-exempt studies applicable to significant-risk or non-significant risk devices
> IDE exempt studies

  • Writing / review of submission documents (i.e., study protocol, informed consent, Investigator’s Brochure, Case Report Form, other documents) for compliance with applicable US requirements and recognized standards including:

> 21 CFR 812, Investigational Device Exemptions (IDEs)
> 21 CFR 50, Protection of Human Subjects and Informed Consent
> 21 CFR 54, Financial Disclosure of Investigators
> 21 CFR 56, Institutional Review Boards
> 21 CFR 11, Electronic records and signatures
> FDA-recognized standard, ISO14155

  • Determination of required study compliance with 21 CFR part 812 (exempted, abbreviated, full requirements)
  • Regulatory review of technical documents, such as, Risk Analysis, Instructions for Use,
  • Institutional Review Board (local or central) submissions
  • IDE applications to FDA
  • Submissions of amendments, renewals, yearly reports, etc. as required
Element not found in

The DLC Clinical Study services are managed from our headquarters in the historical centre of Rome, Italy. Contact us either by e-mail for a confidential discussion about your project, or call Daniela Karrer, VP Operations and Clinical Affairs, on +39 06 578 2665.